Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal, showing promise for relacorilant in treating platinum-resistant ovarian cancer. The ROSELLA trial ...

Results will support a New Drug Application (NDA) in the United States and a Marketing Authorization Application (MAA) in Europe Relacorilant plus nab-paclitaxel has the potential to become a new ...

The data will be presented in a late-breaking oral presentation on Monday, June 2, 2025. The ROSELLA trial is being conducted in collaboration with The GOG Foundation, Inc. (GOG-F), the European ...

Rosella is now under development at 139 S. Cortez St., in what had been Fullblast Brunch (which closed over the summer) and prior to that the first location of Ruby Slipper Café. Rosella is ...

The data will be presented in a late-breaking oral presentation on Monday, June 2, 2025. Title: ROSELLA: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel ...

CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025 Corcept Therapeutics Incorporated (NASDAQ: CORT), a ...